No abstract

No abstract

Two unsymmetrical 1,2,4,5-tetrazine derivatives, (6-(3,5-dimethyl-1H-pyrazol-1-yl)-1,2,4,5-tetrazin-3-ylamino)methanol (C 9 H 13 N 7 O, 3) and 4-(6-(3,5-dimethyl-1H-pyrazol-1-yl)-1,2,4,5-tetrazin-3-yl) morpholine (C 11 H 15 N 7 O, 4), were synthesized from 3,6-bis(3,5-dimethyl-1H-pyrazol-1-yl)-1,2,4,5-tetrazine and the corresponding aliphatic amine (2-aminoethanol and morpholine, respectively), there structures were confirmed by single-crystal X-ray diffraction methods. Both molecules have very similar bond length and angle patterns, The crystal structures show that compound 3 is stabilized by intermolecular O-H-N, N-H-O hydrogen bonds and p-p interactions, while compound 4 is stabilized by p-p interactions. The structure analyses establish that compound 3 belongs to the monoclinic system, space group P2(1)/c, with crystal data a = 6.979(2) Å , b = 9.563(3) Å , c = 16.542(5) Å , V = 1084.4(5) Å 3 , Z = 4, F(000) = 496, R 1 = 0.0488, wR 2 = 0.1063. Compound 4 belongs to the orthorhombic system, space group P2(1)2(1)2(1), with crystal data a = 6.544(14) Å , b = 12.085(3) Å , c = 15.753(4) Å , V = 1245.7(5) Å 3 , Z = 4, F(000) = 552, R 1 = 0.0403, wR 2 = 0.0913.

No abstract

A series of 6-alkoxy-3-aryl-[1,2,4]triazolo[4,3- b][1,2,4,5] tetrazine derivatives is synthesized and evaluated for their antitumor activities. These compounds exhibit potent antiproliferative activities against A549, Bewo, and MCF-7 cells. Molecular docking is performed to study the inhibitor–c-Met kinase interactions, and the results show that 6-ethoxyl-3-phenylethyl-[1,2,4]triazolo[4,3- b][1,2,4,5] tetrazine is potently bound to c-Met kinase with two hydrogen bonds and one π–π interaction. Based on these preliminary results, it is thought that compound 6-ethoxyl-3-phenylethyl-[1,2,4]triazolo[4,3- b][1,2,4,5] tetrazine with potent inhibitory activity may be a potential anticancer agent.